Summary
Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative medicines for diseases with unmet medical need. The company offers products in various therapeutic areas including cardiovascular, respiratory, inflammation, liver diseases, cancer and HIV/AIDS. Gilead operates through more than 40 marketing subsidiaries in the in Europe, North America, South America, Asia-Pacific, the Middle East, Africa and Australia. The company enters into partnerships with organizations in science, academia and business to develop innovative medicines. It continues to add to its existing portfolio of products through internal discovery and clinical development programs; and through a product acquisition and in-licensing strategy. Gilead is headquartered in Foster City, California, the US.
Gilead Sciences Inc (GILD) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Gilead Sciences Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Gilead Sciences Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Gilead Sciences Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Gilead Sciences Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Gilead Sciences Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Gilead Sciences Inc, Medical Equipment, Deal Details 11
Debt Offering 11
Gilead Sciences Raises USD0.5 Billion in Public Offering of 1.95% Notes Due 2022 11
Gilead Sciences Raises USD0.75 Billion in Public Offering of 2.5% Notes Due 2023 12
Gilead Sciences Raises USD1.25 Billion in Public Offering of 2.95% Notes Due 2027 13
Gilead Sciences Raises USD0.75 Billion in Public Offering of 4% Notes Due 2036 15
Gilead Sciences Raises USD1.75 Billion in Public Offering of 4.15% Notes Due 2047 16
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 18
Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 19
Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 20
Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 22
Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 23
Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 25
Gilead Sciences Inc - Key Competitors 27
Key Employees 28
Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 35
Financial Announcements 35
Feb 07, 2017: Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results 35
Nov 01, 2016: Gilead Sciences Announces Third Quarter 2016 Financial Results 37
Jul 25, 2016: Gilead Sciences Announces Second Quarter 2016 Financial Results 39
Apr 28, 2016: Gilead Sciences Announces First Quarter 2016 Financial Results 41
Feb 02, 2016: Gilead Sciences Announces Fourth Quarter and Full Year 2015 Financial Results 43
Corporate Communications 46
Jan 03, 2017: Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head 46
Nov 16, 2016: Gilead Sciences Announces Promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations 47
Aug 23, 2016: Kelly A. Kramer Joins Gilead Sciences’ Board of Directors 48
May 24, 2016: Gilead Sciences Announces Appointment of Kevin Young CBE as Chief Operating Officer and Martin Silverstein, MD as Executive Vice President, Strategy 49
Feb 01, 2016: Gilead Announces Promotion of Katie Watson to Executive Vice President, Human Resources 50
Jan 29, 2016: Gilead’s John C. Martin, PhD to Assume Role of Executive Chairman of the Board; John F. Milligan, PhD to Be Appointed Chief Executive Officer and Director 51
Jan 29, 2016: AHF: Gilead Billionaire CEO John Martin Steps Down 52
Government and Public Interest 53
Aug 11, 2016: ATF Urges Treasury and IRS to Act Against Gilead Science’s Massive Offshore Tax Dodging 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54
List of Tables
Gilead Sciences Inc, Medical Equipment, Key Facts, 2016 1
Gilead Sciences Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
Gilead Sciences Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Gilead Sciences Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Gilead Sciences Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Gilead Sciences Inc, Deals By Market, 2011 to YTD 2017 9
Gilead Sciences Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Gilead Sciences Raises USD0.5 Billion in Public Offering of 1.95% Notes Due 2022 11
Gilead Sciences Raises USD0.75 Billion in Public Offering of 2.5% Notes Due 2023 12
Gilead Sciences Raises USD1.25 Billion in Public Offering of 2.95% Notes Due 2027 13
Gilead Sciences Raises USD0.75 Billion in Public Offering of 4% Notes Due 2036 15
Gilead Sciences Raises USD1.75 Billion in Public Offering of 4.15% Notes Due 2047 16
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 18
Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 19
Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 20
Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 22
Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 23
Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 25
Gilead Sciences Inc, Key Competitors 27
Gilead Sciences Inc, Key Employees 28
Gilead Sciences Inc, Other Locations 30
Gilead Sciences Inc, Subsidiaries 30
List of Figures
Gilead Sciences Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 1
Gilead Sciences Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 1
Gilead Sciences Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 1
Gilead Sciences Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 1
Gilead Sciences Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Gilead Sciences Inc, Medical Equipment, Deals by Type, 2011 to YTD 2017 7
Gilead Sciences Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Gilead Sciences Inc, Medical Equipment, Deals by Market, 2011 to YTD 2017 9